DHR Health
Research Trials
Active Recruitment for Clinical Trials
The DHR Health Institute for Research and Development has clinical trials that are actively recruiting qualified patients. For more detailed information about inclusion and exclusion criteria please contact the Research Department at 956-362-2390.
Neuroscience
- Coordinated, Collaborative, Comprehensive, Family-Based, Integrated, And Technology-Enabled Care: A Comparative Effectiveness Randomized Trial To Improve Stroke Care Delivery (C3FIT)
- Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PREVENTABLE)
- Cladribine Tablets: Observational Evaluation Of Effectiveness And Patient-Reported Outcomes (Pros) In Suboptimally Controlled Patients Previously Taking Oral Or Infusion Disease Modifying Drugs (Dmds) For Relapsing Forms Of Multiple Sclerosis (RMS) (MASTER-2)
- A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing The Efficacy And Safety Of LOU064 100 Mg BID Versus Teriflunomide 14 Mg QD In Participants With RMS, Followed By Extended Treatment With Open-Label LOU064
Liver
- The Texas Hepatocellular Carcinoma Consortium (THCCC); Risk Stratification For and Early Detection of Liver Cancer (U01)
- A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
- Single-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
- A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis
- An Observational Follow-Up Study for Subjects who have Participated in Aldafermin NASH Study 18-0108 (ALPINE 2/3)
- An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects with Confirmed Non-Alcoholic Steatohepatitis
- Merck Sharp and Dohme LLC, (a subsidiary of Merck & Co. Inc., Rahway, New Jersey, USA)/ A phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.
- Ascend-nash: A Phase 2B, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of CRV431 In Adult Subjects With Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis
- A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Remetirom on Liver-Related OUtcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)
Endocrinology
- SPRUCE 203: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
- SPRUCE 204: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
- INHALE: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus
COVID-19
- ACTIV-2: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)
- ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
- I-SPY COVID Trial: An Adaptive Platform Trial to Reduce Mortaility and Ventilator Requirements for Critically Ill Patients
- ACTIV-4A ACUTE: A Multicenter, Adaptive, Randomized, Open Label Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults with COVID-19
Biospecimen Collection
- Various Cancers Matched Sets
- Colon Screening
- Newly Diagnosed Colorectal Cancer
- Fresh tissue- Various Cancer Types
- Whole Blood- Various Cancer Types
- Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas
- Liquid vs Tissue Biopsy Concordance in Samples of 1st Suspected BCa Recurrence & Metastasis
- Solid Tumors- Whole Blood
- Irritable Bowel Disease - Whole Blood
- CRC Adenocarcinoma - Whole Blood
- Healthy Control, CRC, AA - Whole Blood
- Various Cancers - Whole Blood
- LPC-001: Cancer Malignancy Longitudinal Project
Cardiology
- ORION-10 A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
- ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
- Tracking treatment pathways in adult patients with hyperkalemia (TRACK): A prospective, non-interventional, longitudinal study of the treatment journey of adult patients with hyperkalemia
Oncology
- Advanced Fibrosis and Hepatocellular Carcinoma in South Texas
- Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)
- Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
- Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
- Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
- Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
- A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial)
- A Randomized Phase II Study of Intrabucally Administered Electromagnetic Fields versus Placebo for Patients with Child-Pugh A or B Advanced Hepatocellular Carcinoma
Neonatology
- AL46- Growth and Tolerance of Preterm Infants Fed an Experimental Human Milk Fortifier
- Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
- SEQaBOO: SEQuencing a Baby for an Optimal Outcome
- A 26-Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26-Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age
